期刊文献+

胃癌P-糖蛋白和p53蛋白协同表达的意义 被引量:6

Co-expression of P-glycoprotein and p53 protein in gastric carcinoma
暂未订购
导出
摘要 目的 :探讨P糖蛋白和 p5 3蛋白在胃癌中的协同表达意义。 方法 :应用免疫组化方法检测 2 5 9例术前未进行化疗的胃癌组织中多药耐药基因产物P糖蛋白和 p5 3蛋白的表达。 结果 :P gp和p5 3在胃癌中的表达分别为 2 6 2 5 % (6 8/ 2 5 9)和37 0 1% (96 / 2 5 9)。P gp表达与胃癌的组织学类型、浸润深度和淋巴结转移状况无关 (P >0 0 5 ) ;p5 3除与淋巴结转移状况有关外 (P <0 0 0 1) ,与组织学类型和浸润深度无关 (P >0 0 5 )。P gp在 p5 3阳性的病例中的表达明显高于 p5 3阴性的病例 ,即75 %P gp阳性的病人同时伴有 p5 3阳性。 结论 :P gp和p5 3常协同表达于胃癌组织中 。 Purpose To investigate the correlation of the co expression of P glycoprotein (P gp) and p53 protein in gastric carcinoma. Methods Two hundred fifty nine patients with gastric carcinoma, which had not been treated by chemotherapy before surgery, were studied for the expression of P gp and p53 protein using immunohistochemistry. Results P gp and p53 were detected in 26 25%(68/259) and 37 01% (96/259), respectively. Correlation was not observed between P gp expression and histological grading, invasive depth and lymph node metastases( P >0 05). p53 expression was not correlated with histological grading and invasive depth ( P >0 05) but with lymph node metastases ( P <0 001). P gp expression was significantly higher in p53 positive than in p53 negative tumors( P <0 001). 75% of P gp positive tumors were also p53 positive. Conclusion Co expression of p53 and P gp is common,which is a better predictive factor for clinical chemoresistance and for prognosis in gastric carcinoma.
机构地区 福建省立医院
出处 《临床与实验病理学杂志》 CAS CSCD 2000年第6期478-480,共3页 Chinese Journal of Clinical and Experimental Pathology
关键词 胃肿瘤 免疫组织化学 P-糖蛋白 P53蛋白 gastric neoplasms glycoproteins protein, p53 immunohistochemistry
  • 相关文献

参考文献2

二级参考文献14

共引文献12

同被引文献32

  • 1黄杰雄.增殖细胞核抗原的研究进展[J].国外医学(生理病理科学与临床分册),1994,14(1):9-11. 被引量:94
  • 2王江,倪灿荣.p53、ras、c-erbB-2癌基因产物在大肠癌和大肠息肉中的表达[J].中华病理学杂志,1994,23(2):97-99. 被引量:56
  • 3谢佐福.肿瘤细胞耐药性的胞外影响机制[J].国外医学(肿瘤学分册),1996,23(3):151-153. 被引量:7
  • 4Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistance MRP-transfected human tumor cells[J]. Cancer Res,1994,54: 5902-5904.
  • 5Armstrong RN. Structure, catalytic mechanism and evolution of the glutathione transferase[J]. Chem Res Toxico, 1997,10:2-5.
  • 6Nooter K,Stoter G. Moleculer mechanisms of multidrug resistance in cancer chemotherapy[J]. Pathol Res Pract, 1996, 192(7) :768-780.
  • 7Koshiyama M,Fujii H,Kinezaki M,et al. Correlation between TOPO- Ⅱ alpha expression and chemosensitivity testing for TOPO- Ⅱ -targeting drug in gynaecological carcinomas[J]. Anticancer Res, 2001,21(2A) :905-910.
  • 8Kakeji Y, Korenaga D, Tsujitani S, et al. Gastric cancer withp53 overexpression has high potential for metastasising tolymph nodes. Br J Cancer 1993; 67:589 - 93
  • 9Koide N, Nishio A, lgarashi J, et al. Alpha-fetoprofein protein-producing gasic cancer: histochemical analysis of cell proliferation apopsis and angiogenesis. Am J Gastroenterol 1999; 94(6): 1658 - 63
  • 10Tokunaga A, Onda M, Okuda T, et al. Clinical significance of epidermal growth factor (EFG) preceptor and c-erbB-2 inhuman gastric cancer. Cancer 1995:75 (6Suppl): 1418 - 25

引证文献6

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部